Insulin resistance and defective estrogen effect are collaborating in cancer risk
What is it about?
Deepening insulin resistance leads to the defect of estrogen synthesis and signaling, while low estrogen level or estrogen receptor defect inhibits cellular glucose uptake leading to insulin resistance.
Why is it important?
Patients with insulin resistance and/or with estrogen signaling defect may be treated by insulin sensitizers and/or exogenous estrogen (oral contraceptive, postmenopausal hormone replacement) for the prevention of cancer development. Moreover, higher estrogen doses are effective even against advanced cancers.
The following have contributed to this page: professor Zsuzsanna Suba
In partnership with: